Glycosylation of recombinant adeno-associated virus serotype 6

Yuki Yamaguchi; Kentaro Ishii; Sachiko Koizumi; Hiroaki Sakaue; Takahiro Maruno; Mitsuko Fukuhara; Risa Shibuya; Yasuo Tsunaka; Aoba Matsushita; Karin Bandoh; Tetsuo Torisu; Chie Murata-Kishimoto; Azusa Tomioka; Saho Mizukado; Hiroyuki Kaji; Yuji Kashiwakura; Tsukasa Ohmori; Atsushi Kuno; Susumu Uchiyama

doi:10.1016/j.omtm.2024.101256

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Glycosylation of biopharmaceuticals can affect their safety and efficacy. Glycans can occur on recombinant adeno-associated viruses (rAAVs) that are used for gene therapy; however, the types of glycans that attach to rAAVs are controversial. Here, we conducted lectin microarray analyses on six rAAV serotype 6 (rAAV6) preparations that were produced differently. We demonstrate that

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yamaguchi et al. (2024) studied this question.

synapsesocial.com/papers/68e6d971b6db64358765580e https://doi.org/10.1016/j.omtm.2024.101256

View Full Paper

Ask AI

Bookmark

Share

Glycosylation of recombinant adeno-associated virus serotype 6

Ask about this paper

Abstract

Discussion

Cite This Study

Glycosylation of recombinant adeno-associated virus serotype 6

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading